Abstract: The present invention is related to an oxime of the 13?-ethyl-17?-hydroxi-18,19-dinorpregn-4-en-20-in-3-o (norelgestromin) of Formula I with a relation of isomers E/Z between 1.3 and 1.6 and the method of producing the oxime.

Abstract: A new crystalline form of the Zoledronic acid, characterized by its X-rays diffractogram as well as by its spatial atomic distribution in the red crystalline and its curves of thermal analysis. There is also included a method to obtain this crystalline form, which includes the synthesis of the corresponding acid and the pharmaceutical composition this crystalline form comprises.

Abstract: An improved method for preparing N-[3(3-cyanopyrazole[1,5-a]pyrimidine-7-yl)phenyl]-N-ethyl-acetamide having the FORMULA I: in which the product in question is obtained in “a single step” starting with N-[3-[3-(dimethylamine)-1-oxo-2-propenyl]phenyl]acetamide (II) according to the following sequence: In a first stage N-[3-[3-(dimethylamine)-oxo-2-propenyl]phenyl]acetamide (II) is added in portions to a suspension of sodium hydride in dimethylformamide in the presence of ethyl iodide. The resulting suspension of compound (III) (N-[3-[3-(dimethylamine)-1-oxo-2-propenyl]phenyl]-N-ethyl-acetamide) is diluted with water until solution A is obtained which is used as it is. Subsequently, solution A is added to solution B of 3-amino-pyrazole-4-carbonitrile IV) in aqueous DMF/hydrochloric acid.

Abstract: An improved method for preparing N-[3(3-cyanopyrazole[1,5-a]pyrimidine-7-yl)phenyl]-N-ethyl-acetamide having the FORMULA I: 1